Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Clasificación en acciones #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Precio por acción
$0.0001
Última sincronización: 2023-05-22
Capitalización bursátil
$10.03K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio NuGenerex Immuno-Oncology, Inc. (NUGX)

Categoría

Ganancias de NuGenerex Immuno-Oncology, Inc. (NUGX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di NuGenerex Immuno-Oncology, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de NuGenerex Immuno-Oncology, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE